Board
Members

Lachlan joined the Cure4CF board in 2015. He knows first-hand the effects of cystic fibrosis and wanted to join the fight and support the Foundation’s efforts to find a cure.  At the 2018 Cure4CF Annual General Meeting, Lachlan was unanimously voted in as Deputy Chairman, a role which he describes as an honour and privilege. Lachlan is currently Centre Manager at Westfield Marion. He has worked for Westfield for the past 12 years and has experience in a number of marketing and management roles across Victoria and South Australia.

Greg is an experienced manufacturing executive with expertise in engineering and continuous process operations. He is currently General Manager, Glass for Orora Limited.

Greg has been a manufacturing plant manager in Melbourne, Sydney and Brisbane over a 15 year period. The Sydney plant is one of the largest glass plants in the world with four furnaces, ten machine lines and 460 employees.

Managing more than 450 employees across two sites at the Spotswood Glass Plant and Box Hill Engineering facility, Greg led a major restructuring and business turn around in safety, quality, production efficiency and industrial relations relationships.

Jenna is a legal practitioner and business professional with experience in private practice and not for profit sectors. Jenna currently works at AnglicareSA as one of their Legal Counsel, assisting in identifying risks to the organisation and helping achieve strategic and operational goals. She also brings significant experience from her previous role, specialising in business advisory, taxation and structuring issues.

Jenna holds a Bachelor of Laws (Honours) and is a Legal Practitioner admitted to the Supreme Court of South Australia. She is also a Chartered Accountant, and holds a Bachelor of Commerce.

Jenna is passionate about assisting the community. She joined the board in 2020 and is excited about working with Cure4CF towards the delivery of its vision.

Matt has worked in the life sciences industry for over 20 years, with experience in business development, consulting and strategic planning roles across industry, government and academia. He is currently a Client Engagement Facilitator at the Australian National Fabrication Facility, an organization that supports advancing innovative manufacturing for high value products, with cutting edge equipment and world-class expertise. Matt has previously held senior management roles in the biotechnology sector, state government and several Australian universities. He has extensive experience in all aspects of the research funding lifecycle.

Matt holds a Bachelor of Biotechnology with first class honours, a PhD in Medicine and a Graduate Certificate in Applied Finance. He joined the Board in November 2021 and is a member of the Research and Commercialisation subcommittee. He is passionate about the “bench to bedside” translation of research and supporting genuine collaboration between industry and research organisations. 

   Phil holds a Ph.D. from Monash University, which was followed by post-doctoral training at the Murdoch Institute in Melbourne and University College London. He also holds a MBA from the University of Sydney. Dr Kearney began his career as an academic as Head of the Research Laboratory in one of Australia’s leading Haematology Departments, at St Vincent’s Hospital Sydney for over 10 years.  The theme of the laboratory was antisense and ribozyme mediated ablation of bcr-abl expression in Chronic Myeloid Leukaemia. After 12 years at SVH he moved to Europe to lead preclinical oncology at ActiveBiotech Sweden, and then as Head of Biology at Santaris Pharma. In the latter, the highlight was the first publication of regulation of a microRNA in NHP , in the prestigious Nature journal.

He joined Merck Sharp & Dohme Australia in 2007 as the key scout for innovative research and development in Australia, New Zealand, India and some parts of South East Asia. In his time with MSD, he has led or been part of the team who have transacted deals worth more than $2B, covering acquisition, licenses, and R&D collaborations with biotechs and academic institutions.

Phil joined Axelia Oncology in Feb 2021.

Greg has considerable experience in the promotion of cystic fibrois and raising funds to support research into a cure. Greg was also on the board of The Cystic Fibrosis Association of South Australia Inc.

Greg is currently managing his own business and has significant senior management experience in the mining, automotive and manufacturing industries.

   David Coluccio is Founder and Principal of Senexus, which offers independent advice and manages the placement process for families seeking an aged care home for their loved one in Adelaide.

Prior to starting Senexus, David spent more than ten years in a variety of management roles including as General Manager of the Women’s & Children’s Hospital Foundation where he raised funds for and project managed the redevelopment of the Playdeck as well as being instrumental in the fundraising and construction of the Starlight Room. During this time he also completed an MA (International Relations) and an MBA at the University of Adelaide and is a Graduate Member of the Australian Institute of Company Directors.

Passionate about ensuring access to quality aged care for those in need, David founded Senexus to help families through the stressful and emotional process of placing a loved one into residential aged care. David coordinates all aspects of admitting a loved one into residential aged care, including undertaking the search for a suitable aged care home and advising on the costs of care.

From 2009 to 2018, David was a director, and then Chairman, of the Cure4CF Foundation and in 2022 he joined the Cure4 CF as a patron.

In 2021, David was awarded the Medal of the Order of Australia (OAM) for services to the cystic fibrosis community.